Cargando…
Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group
Main objective of this study was to confirm that surgery alone is an effective and safe treatment for localised resectable neuroblastoma except stage 2 with amplified MYCN gene (MYCNA). Of 427 eligible stages 1–2 patients, 411 had normal MYCN and 16 had MYCNA. Of the 288 stage 1 patients with normal...
Autores principales: | De Bernardi, B, Mosseri, V, Rubie, H, Castel, V, Foot, A, Ladenstein, R, Laureys, G, Beck-Popovic, M, de Lacerda, A F, Pearson, A D J, De Kraker, J, Ambros, P F, de Rycke, Y, Conte, M, Bruzzi, P, Michon, J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567095/ https://www.ncbi.nlm.nih.gov/pubmed/18766186 http://dx.doi.org/10.1038/sj.bjc.6604640 |
Ejemplares similares
-
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018) -
Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy
por: Rubie, H, et al.
Publicado: (2003) -
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group
por: Ambros, Inge M., et al.
Publicado: (2020) -
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
por: Schleiermacher, G, et al.
Publicado: (2011) -
The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)